The Department of Health and Human Services has reached an agreement with Pfizer to extend patient access to Paxlovid, which is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients.
The drug is targeted at patients 12 years old and older who are at high risk for progression to severe COVID-19, including hospitalization or death.
